Cytokinetics to Unveil 371-Patient Analysis Showing Exercise Capacity Gains and ECG Benefits
Cytokinetics will present pooled data from 371 symptomatic oHCM patients at ACC showing its myosin inhibitor aficamten improved exercise capacity versus metoprolol and placebo and exhibited safe interruption in 182 patients. Supplemental analyses revealed significant ECG improvements (ST changes OR 0.23; LVH strain OR 0.15; P<0.001).
1. ACC Presentations Overview
Cytokinetics announced four scientific presentations at the American College of Cardiology session focused on MYQORZO (aficamten) in obstructive hypertrophic cardiomyopathy. The data derive from SEQUOIA-HCM, MAPLE-HCM and FOREST-HCM trials, covering efficacy, safety, subgroup analyses and electrocardiographic endpoints.
2. Pooled Exercise Capacity Data
A pooled analysis of SEQUOIA-HCM and MAPLE-HCM included 371 patients randomized to aficamten monotherapy, metoprolol monotherapy or placebo. Aficamten showed superior improvements in exercise capacity compared to both metoprolol and placebo across clinically relevant measures.
3. Treatment Interruption Safety
An analysis of 182 participants evaluated a four-week aficamten washout followed by reinitiation. Washout was not linked to rebound cardiac events, with only 0.7% experiencing mild heart-failure worsening, and reinitiation restored therapeutic response without safety concerns.
4. ECG and Hypertension Analyses
Electrocardiographic data from SEQUOIA-HCM showed aficamten reduced ST segment changes (adjusted OR 0.23; 95% CI 0.11–0.46) and LVH strain patterns (adjusted OR 0.15; 95% CI 0.06–0.41). A hypertension subgroup of 175 patients demonstrated similar rates of uncontrolled hypertension (34% vs. 25%; P=0.38) with aficamten versus metoprolol.